<DOC>
	<DOCNO>NCT02289794</DOCNO>
	<brief_summary>This Phase I multi-center placebo control study conduct healthy woman history recurrent urinary tract infection ( UTI ) age 18 70 year .</brief_summary>
	<brief_title>Vaccine Against Escherichia Coli Infection</brief_title>
	<detailed_description>GlycoVaxyn Swiss company develop multivalent bioconjugate vaccine prevention E.coli-infections . Cystitis common UTI , however kidney infection bacteremia possible . The E. coli bacterium responsible 85 % UTIs . The objective trial ass safety ability elicit immune response candidate vaccine well effectiveness vaccine reduction UTIs .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Urinary Tract Infections</mesh_term>
	<mesh_term>Escherichia coli Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Female subject history recurrent UTI , define : ≥ 3 UTI independent episode previous 12 month ≥ 2 UTI episode last 6 month . At least one UTI last 5 year cause E. coli ( single pathogen part polymicrobial infection ) cultureconfirmed documented 2 . Age ≥ 18 ≤ 70 year 3 . Subjects healthy state without ongoing suspect symptomatic UTI screen visit injection day ( V2 ) 4 . General good health , without clinically significant medical history , physical examination finding clinical laboratory abnormality per clinical judgment investigator 5 . Willingness participate study aspect protocol explain fully understood , write informed consent form obtain 1 . History 10 recurrent UTIs year screen visit 2 . Use shortterm urinary catheter within 7 day prior screen 3 . Use permanent catheter within 30 day prior screen 4 . History unresolved urinary tract diseases/abnormalities 5 . Evidence impair immune function 6 . Significant cardiovascular , liver , renal disease and/or insufficiency 7 . Uncontrolled diabetes mellitus 8 . Significant abnormality screen result hematology , serum chemistry urinalysis 9 . Positive test HIV , and/or evidence HBV HCV 10 . BMI &gt; 34 11 . Previous immune stimulatory therapy UTI prevention ( Urovaxom® , Strovac® Urovac® ) last 3 month , plan use study period 12 . Current use medication know affect immune function ( e.g . corticosteroid ≥0.5 mg/kg Body weight/day ) 13 . Use UTIrelated vaginal estrogen treatment newly start less 6 month injection continue study plan start active study period 14 . Use antibiotic therapy within 1 week precede injection 15 . Planned use postcoital antibiotic UTI prevention study period 16 . Any vaccination plan within 30 day 30 day injection 17 . Participation clinical trial 60 day precede enrolment duration study 18 . Previous treatment immunoglobulin blood product 3 month precede injection 19 . Known hypersensitivity component vaccine 20 . Presence significant medical psychiatric condition opinion investigator precludes participation study 21 . Acute illness time injection 22 . Women child bear potential either positive pregnancy test refuse use effective contraception 23 . Women lactate time throughout study period 24 . Subjects elective surgical intervention , plan study period 25 . Any significant finding opinion Investigator would increase risk adverse outcome participating study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Bioconjugate vaccine</keyword>
	<keyword>Urinary tract infection</keyword>
</DOC>